Characterization of Sleep Disorders in Patients With Specific Learning Disabilities According to Age, Sex, Associated Comorbidities and Treatments

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Observational
SUMMARY

Objective: The main objective of this study is to assess the frequency and nature of sleep disorders in patients (both adults and children) with specific learning disorders, with or without ADHD. Secondary

Objectives: * Characterize the SLD patient population in France by considering age and gender: o Determine the prevalence of co-morbidities, such as: ADHD Anxiety and depressive disorders Other reported medical conditions * Assess the types of care provided (medication or other) for both children and adults * Determine the frequency of SLD in a familial context * Identify whether the following factors are associated with a higher frequency of sleep disorders: * Single SLD vs. multiple SLD * The presence of ADHD, anxiety-depressive disorders, or other medical conditions alongside SLD * Demographic characteristics (age, gender, etc.) * Family history of SLD among relatives (parents and siblings) * Medication use

Eligibility
Participation Requirements
Sex: All
Minimum Age: 4
Healthy Volunteers: f
View:

• Children, adolescents and adults with a specific learning disability (dyslexia, dysorthography, dyscalculia, dysgraphia, dyspraxia, dysphasia).

• ≥ 4 ans

Locations
Other Locations
France
Hospices Civils de Lyon
RECRUITING
Bron
Contact Information
Primary
Patricia FRANCO, Pr
patricia.franco@chu-lyon.fr
0427856052
Backup
Aurore GUYON
aurore.guyon@chu-lyon.fr
0427855247
Time Frame
Start Date: 2025-04-16
Estimated Completion Date: 2026-04
Participants
Target number of participants: 1000
Treatments
Children
Children (4 \< 18 years old) with specific learning disabilities, associated or not with others medical condition
Adult
Adult (\> 18 years old) with specific learning disabilities, associated or not with others medical condition
Sponsors
Leads: Hospices Civils de Lyon

This content was sourced from clinicaltrials.gov